Active, not recruitingPhase 3NCT03206671
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital Muenster
- Principal Investigator
- Birgit Burkhardt, Prof. Dr. Dr.University Hospital Muenster, Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie
- Intervention
- Rituximab window(drug)
- Enrollment
- 650 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2027
Study locations (30)
- Univ.Klinik für Kinder- und Jugendheilkunde Graz, Klin. Abteilung für pädiatrische Hämato-Onkologie, Graz, Austria
- Univ.Klinik für Kinder- und Jugendheilkunde Innsbruck, Universitätsklinik für Pädiatrie I, Innsbruck, Austria
- Klinikum Klagenfurt am Wörthersee, Abteilung für Kinder- und Jugendheilkunde, Klagenfurt, Austria
- Kepler Universitätsklinikum, Med Campus IV / Onkologie, Linz, Austria
- LKH Salzburg, Universitätsklinik für Kinder- und Jugendheilkunde, Kinderonkologie, Salzburg, Austria
- St. Anna Kinderspital, Vienna, Austria
- Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czechia
- Børneonkologisk afsnit 303B, Børneafdelingen, Aalborg Universitetshospital Nord, Aalborg, Denmark
- Børn og Unge afsnit 4, Børneafdelingen, Aarhus Universitetshospital Skejby, Aarhus, Denmark
- Børneonkologisk afsnit 5054, BørneUngeKlinikken, Juliane Marie Centret, Rigshospitalet, Copenhagen, Denmark
- Børneonkologisk afsnit H2, H. C. Andersen Børnehospital, Odense Universitetshospital, Odense, Denmark
- Helsinki University Hospital, Children´s Hospital, Dept of Pediatric Hematology and Oncology, Helsinki, Finland
- Kuopio University Hospital, Paediatric Haematology and Oncology, Kuopio, Finland
- University Hospital of Oulu, Paediatric Haematology and Oncology, Oulu, Finland
- Tampere University Hospital, Paediatric Haematology and Oncology, Tampere, Finland
- +15 more locations on ClinicalTrials.gov
Collaborators
Deutsche Krebshilfe e.V., Bonn (Germany)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03206671 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic